MNOV (MediciNova) Debt-to-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2006. Start your Free Trial

What is MediciNova Debt-to-Asset?

MediciNova's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.20 Mil. MediciNova's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. MediciNova's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $58.12 Mil. MediciNova's debt to asset for the quarter that ended in Sep. 2024 was 0.00.

MediciNova Debt-to-Asset Historical Data

The historical data trend for MediciNova's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediciNova Debt-to-Asset Chart

MediciNova Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

MediciNova Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	-	-	-	-

Competitive Comparison of MediciNova's Debt-to-Asset

For the Biotechnology subindustry, MediciNova's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediciNova's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediciNova's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where MediciNova's Debt-to-Asset falls into.

MediciNova Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

MediciNova's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.216	+	0)	/	66.27
	=	0.00

MediciNova's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.202	+	0)	/	58.119
	=	0.00

MediciNova (NAS:MNOV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

MediciNova Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of MediciNova's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

MediciNova Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (NAS:MNOV) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

4875:Japan

Address

4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037

Website

https://www.medicinova.com

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

Executives

Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
Hideki Nagao	director	4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122
Jason J Kruger	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Douglas Paulin	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Gaeta Federico C.a.	officer: Chief Scientific Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
3d Investment Partners Pte. Ltd.	10 percent owner	250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
3d Opportunity Master Fund	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Carolyn Beaver	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Stepanow Edward C Jr.	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Kazuko Matsuda	officer: Chief Medical Officer	C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yuichi Iwaki	director	C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Carla Reyes	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Yoshio Ishizaka	director	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yutaka Kobayashi	director	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Geoffrey Obrien	officer: Vice President	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037